Press release - 07/05/2026 MRI is a better indicator than BMI of when body fat becomes dangerous MRI analysis of fat and muscle distribution in more than 66,000 people provides a more accurate assessment of health risks / Poor muscle quality poses an additional risk / Study provides reference values based on age, sex, and heighthttps://www.gesundheitsindustrie-bw.de/en/article/press-release/mri-better-indicator-bmi-when-body-fat-becomes-dangerous
Press release - 30/04/2026 A single swab is sufficient: Study paves the way for simplified tuberculosis diagnosis Led by researchers from Heidelberg Faculty of Medicine at Heidelberg University and the University of California, San Francisco (USA), an international research team has evaluated a novel approach for the diagnosis of pulmonary tuberculosis. The method enables detection of Mycobacterium tuberculosis without laboratory infrastructure, within a markedly shorter time frame than conventional diagnostics, and using a simple swab. https://www.gesundheitsindustrie-bw.de/en/article/press-release/single-swab-sufficient-study-paves-way-simplified-tuberculosis-diagnosis
Press release - 30/04/2026 More collaboration, more impact: The Innovation Alliance Foundation Freiburg adopts a new resolution The University of Freiburg works closely with partners from various sectors including academia, business, politics and public administration through the Innovation Alliance Foundation Freiburg. The resolution that has been adopted reinforces the shared goal of establishing Freiburg as an attractive innovation hub with international appeal.https://www.gesundheitsindustrie-bw.de/en/article/press-release/more-collaboration-more-impact-innovation-alliance-foundation-freiburg-adopts-new-resolution
Press release - 24/04/2026 New Medical Director of the Department of Nephrology Prof. Dr. Halbritter has served as the new Medical Director of the Department of Nephrology at the Medical Center – University of Freiburg since April 2026. With his expertise, he is enhancing care for patients with kidney disease: The goal is to prevent kidney failure through early diagnosis and the implementation of strategies to slow disease progression. For cases where kidney failure has already occurred, the focus is on organ replacement.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-medical-director-department-nephrology
Press release - 22/04/2026 Higher Biological Age - Higher Cancer Risk Not only actual chronological age, but also individual aging at the molecular level is a key factor in the development of cancer. This was discovered by scientists at the DKFZ and the Saarland Cancer Registry. If the so-called “epigenetic clocks” indicate accelerated biological aging, the likelihood of a cancer diagnosis increases. This finding could help identify at-risk groups and make early detection screenings more targetedhttps://www.gesundheitsindustrie-bw.de/en/article/press-release/higher-biological-age-higher-cancer-risk
Press release - 10/04/2026 New study identifies clinically relevant changes in airway wall thickness in COPD and at-risk individuals A recent study published in the European Respiratory Journal provides important new insights into the early identification and monitoring of chronic obstructive pulmonary disease (COPD). The focus is on airway wall thickness as an imaging marker for structural remodeling processes in the lungs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-study-identifies-clinically-relevant-changes-airway-wall-thickness-copd-and-risk-individuals
Press release - 10/04/2026 Molecular analyses could improve treatment options for a rare soft tissue tumor Desmoplastic small- and round-cell tumor is rare, aggressive, and difficult to treat. Researchers at the National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer Research Center (DKFZ) have comprehensively analyzed 30 tumors and identified potential personalized treatment options for nearly all patients. In some patients, new targeted approaches were able to halt the disease for a surprisingly long time.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-analyses-could-improve-treatment-options-rare-soft-tissue-tumor
Photoimmunotherapy - 09/04/2026 Switching off tumours with light: how photons can be used to target prostate cancer Prostate cancer is the most common cancer among men in Germany. Relapses and the harsh side effects of traditional treatments remain a major challenge, even with advanced surgical techniques. At the University of Freiburg, Dr. Wolf is pioneering the development of photoimmunotherapy. Photoimmunotherapy combines light, antibodies and a specialised dye to precisely target tumour cells - simultaneously 'waking up' the immune system.https://www.gesundheitsindustrie-bw.de/en/article/news/switching-tumours-light-how-photons-can-be-used-target-prostate-cancer
Press release - 07/04/2026 No soft drink before the massage How does sugar affect relaxation exercises? A new study carried out by researchers from the University of Konstanz provides revealing insights into the connection between blood glucose and the autonomic nervous system: The intake of sugar counteracts relaxation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/no-soft-drink-massage
Press release - 02/04/2026 Pocket-sized biomedical technology to become smarter Volkswagen Foundation supports mobile health expert Professor Walter Karlen The Volkswagen Foundation is supporting the Ulm scientist Professor Walter Karlen with more than 940,000 euros from the funding initiative "Momentum - funding for first-time researchers". The engineer has headed the Institute of Biomedical Engineering at Ulm University since 2021. Karlen conducts research in the field of mobile health on so-called Medicine Wearables, i.e. portable technology for recording health data. https://www.gesundheitsindustrie-bw.de/en/article/press-release/pocket-sized-biomedical-technology-become-smarter-volkswagen-foundation-supports-mobile-health-expert-professor-walter-karlen
Press release - 01/04/2026 Digital Assistance System Designed to Prevent Recurrent Heart Disease Women who have experienced a stroke or heart attack are at a higher risk of mortality than men. Fraunhofer researchers want to improve gender-specific aftercare with a customized assistance system – thus helping to prevent further heart disease.https://www.gesundheitsindustrie-bw.de/en/article/press-release/digital-assistance-system-designed-prevent-recurrent-heart-disease
Press release - 30/03/2026 Ulm University funds projects on molecular quantum bits and digital diabetes research Research incubators focus on ideas outside the mainstream Creating scope for innovative projects from various disciplines: That is the aim of the research incubators at Ulm University. The aim is to initiate developments and ideas that could become relevant research areas for the University. In the current call for proposals, the jury has selected two interdisciplinary projects on quantum chemistry and digital, sensor-based diabetes research. https://www.gesundheitsindustrie-bw.de/en/article/press-release/ulm-university-funds-projects-molecular-quantum-bits-and-digital-diabetes-research-research-incubators-focus-ideas-outside-mains
Proof-of-concept study of organoid technology - 26/03/2026 Can organoids improve the treatment of pancreatic cancer? A clinical trial called UNITEPANC is exploring whether organoid-based approaches can improve the treatment of pancreatic cancer. BIOPRO Baden-Württemberg spoke with the study’s principal investigator and pancreatic cancer specialist, Prof. Dr. Thomas Seufferlein of University Hospital Ulm, to discuss the disease more broadly along with the specific aims of the trial. The interview was conducted by Walter Pytlik on behalf of BIOPRO.https://www.gesundheitsindustrie-bw.de/en/article/news/can-organoids-improve-treatment-pancreatic-cancer
Press release - 25/03/2026 The Influence of Lymph Node Architecture on Lymphoma For the first time, researchers have succeeded in mapping the organization of immune cells in human lymph nodes. The study was led by scientists from Heinrich Heine University Düsseldorf, Düsseldorf University Hospital, the DKFZ, the European Molecular Biology Laboratory (EMBL), and the Max Delbrück Center (MDC) in Berlin. They were able to demonstrate why the architecture of healthy lymph nodes is altered in malignant lymphomas.https://www.gesundheitsindustrie-bw.de/en/article/press-release/influence-lymph-node-architecture-lymphoma
Press release - 24/03/2026 Ovarian Cancer: Adipose Tissue Influences the Efficacy of Immunotherapy In ovarian cancer, immunotherapies using checkpoint inhibitors have so far been effective in only a small number of patients. Researchers at the HI-TRON Mainz* have now discovered that lipid metabolism processes in the tumor microenvironment play a decisive role in how well such therapies work. The findings open up new avenues for using immunotherapies in a more targeted manner, increasing their effectiveness, and overcoming resistance.https://www.gesundheitsindustrie-bw.de/en/article/press-release/eierstockkrebs-fettgewebe-beeinflusst-wirksamkeit-der-immuntherapie
Press release - 19/03/2026 Carl-Zeiss-Stiftung Funds Pioneering AI Project at the DKFZ How can artificial intelligence support medical imaging diagnostics in the future and significantly improve patient care? Researchers led by Lena Maier-Hein (German Cancer Research Center, DKFZ, and NCT Heidelberg) have developed an innovative concept to address this question. The Carl Zeiss-Stiftung is funding the MEDAL* project with a total of three million euros.https://www.gesundheitsindustrie-bw.de/en/article/press-release/carl-zeiss-stiftung-funds-pioneering-ai-project-dkfz
Press release - 17/03/2026 Targeting Cancer Drugs More Effectively: First EU Project Integrates Pharmacogenomics into Tumor Boards The Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology (IKP) at the Bosch Health Campus in Stuttgart is leading Europe’s first EU project to systematically integrate pharmacogenomics into molecular tumor boards (MTB). The goal of PGxMTB is to systematically incorporate patients’ genetic factors into treatment decisions, thereby making cancer therapies safer and more effective. https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-cancer-drugs-more-effectively-first-eu-project-integrates-pharmacogenomics-tumor-boards
Press release - 12/03/2026 Brain Diseases: Certain Neurons Are Especially Susceptible to ALS and FTD Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) belong to a spectrum of neurodegenerative diseases with overlapping symptoms. Many patients have a common hallmark: A protein called TDP-43 clumps together in the neurons of the brain to form tiny lumps. Researchers at DZNE and Ulm University Hospital, together with international experts, have now discovered that these pathological changes primarily affect certain cells. https://www.gesundheitsindustrie-bw.de/en/article/press-release/brain-diseases-certain-neurons-are-especially-susceptible-als-and-ftd
Press release - 11/03/2026 Blood Marker for Alzheimer’s May also Be Useful in Heart and Kidney Diseases A certain blood protein regarded as an early indicator of Alzheimer’s disease also appears to play a role in other disorders. Researchers at DZNE and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen have found that elevated levels of phosphorylated tau protein (pTau) also occur in two lesser-known conditions that primarily affect the heart and kidneys.https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-marker-alzheimers-may-also-be-useful-heart-and-kidney-diseases
Press release - 10/03/2026 Advanced melanoma: Antibodies in the blood indicate side effects of immunotherapy Immunotherapies have greatly improved the treatment of metastatic melanoma, but they can cause serious side effects. A study led by researchers from Heidelberg University's Medical Faculty, the Heidelberg University Hospital, and the NCT in Heidelberg now shows that autoantibodies detected in the blood before the start of therapy could help to better assess the individual risk of side effects in patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/advanced-melanoma-antibodies-blood-indicate-side-effects-immunotherapy
Press release - 09/03/2026 Early detection contributes to declining breast cancer mortality rates in Europe The introduction of mammography screening programs in Europe has significantly changed breast cancer diagnoses, accompanied by a decline in breast cancer mortality rates. This is shown by the most comprehensive analyses of population-based data on breast cancer in 21 European countries to date, led by the DKFZ. The most striking finding: after the introduction of screening, significantly more early-stage, less advanced tumors were detected.https://www.gesundheitsindustrie-bw.de/en/article/press-release/early-detection-contributes-declining-breast-cancer-mortality-rates-europe
Press release - 02/03/2026 Novel therapy for Phelan-McDermid syndrome Drug development to be funded with up to 1.7 million euros An international team led by Professor Tobias M. Böckers from Ulm University Medical Centre has been awarded up to 1.7 million euros to develop a novel therapy for a rare, syndromic form of autism. The research project focuses on a gene whose loss of function can manifest itself in severe impairments in language, behaviour and everyday functions of those affected.https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-therapy-phelan-mcdermid-syndrome-drug-development-be-funded-17-million-euros
Press release - 18/02/2026 New centre for cell research Technology impulse for the Lake Constance region: The new Single Cell Centre at the University of Konstanz offers technology and expertise to study cells individually and at high resolution – for applications in medical diagnostics, medication development and basic research at universities.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-centre-cell-research
Press release - 18/02/2026 3D microtumors could revolutionize treatment decisions Chemotherapy is often a central component of treatment for advanced colorectal cancer. However, not every therapy is equally effective for every patient. Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* stem cell institute, and the biotech company Xilis in Utrecht, Netherlands, have now developed a new method for selecting the most effective drug before treatment begins. https://www.gesundheitsindustrie-bw.de/en/article/press-release/3d-microtumors-could-revolutionize-treatment-decisions
Press release - 18/02/2026 Shingles vaccination could slow cognitive decline New findings indicate that a shingles vaccination could not only reduce the risk of cognitive impairment and dementia, but also reduce disease progression among those living with dementia. https://www.gesundheitsindustrie-bw.de/en/article/press-release/shingles-vaccination-could-slow-cognitive-decline